Novartis expands radioligand slate with BoomRay deal valued up to $900M
Novartis inks a up-to-$900 million license for BoomRay’s preclinical radioligand therapy, boosting its radiopharmaceutical portfolio with upfront, milestones and royalties while details of the program aren’t disclosed; the move comes as Telix Pharmaceuticals acquires ITM Isotope Technologies, signaling intensified competition in the radiopharma space alongside Novartis’ Pluvicto and Lutathera.
